Company intelligence / Profile preview

HidraMed Solutions

Ownership: Private
Development stage: Commercial

Overview

HidraMed Solutions has developed and commercialized the patented HidraWear platform, an adhesive-free wound care solution for chronic wounds in difficult-to-dress areas. Clinical trials have demonstrated significant improvements in patient quality of life, pain reduction at dressing changes, and empowerment for self-care. The product is CE marked, FDA registered, ISO 13485 accredited, and has achieved reimbursement status in the UK, US, and Germany. It has won multiple innovation awards including the Irish Times Innovation Award 2020 and Journal of Wound Care Gold Award for Clinical Research 2023.

Therapeutic areas: Dermatology
Modalities: DeviceNon-pharmacological therapy (adhesive-free wound dressing system)
Industry: Consumable Medical Devices

Partnerships

NHS Supply Chain/Drug Tariff Listings (UK distribution/reimbursement)Distribution partners in US and Germany

Beyond the preview

Go deeper on HidraMed Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HidraMed Solutions.

Explore the full profile